GlaxoSmithKline (NYSE:GSK) has been awarded a federal contract that could be worth nearly $95 million if the pharma giant can develop a new antibiotic to combat biothreats such as bubonic plague and ...
A type 1 diabetes drug under development by GlaxoSmithKline has failed in late stage clinical trials. GSK (NYSE:GSK) announced Friday that otelixizumab, an investigational compound for type 1 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results